

Aralez Pharmaceuticals Inc.
Form 8-K
May 10, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 10, 2016**

ARALEZ PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction of
incorporation)

001-37691
(Commission File Number)

98-1283375
(IRS Employer Identification No.)

151 Steeles Avenue East, Milton, Ontario, Canada
(Address of principal executive offices)

L9T 1Y1
(Zip Code)

Edgar Filing: Aralez Pharmaceuticals Inc. - Form 8-K

Registrant's telephone number, including area code: **(905) 876-1118**

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On May 10, 2016, Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada (the Company), issued a press release announcing its results of operations for the quarter ended March 31, 2016. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosures.

As previously announced, the Company will conduct a conference call today, Tuesday, May 10, 2016 at 8:30 a.m. ET, to discuss its 2016 first quarter financial results. The presentation slides to be used during the call will be available on the Investors section of the Company's website (<http://www.aralez.com>) under the Presentations & Webcasts tab beginning at 8:30 a.m. ET on Tuesday, May 10, 2016. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously webcast on the Investors section of the Company's website under the Presentations & Webcasts tab beginning at 8:30 a.m. ET on May 10, 2016, and will remain available for future review for 90 days after the event. The information contained in, or that can be accessed through the Company's website, is not a part of this filing.

Item 9.01. Financial Statements and Exhibits

(d) List of Exhibits

EXHIBIT NO.	DESCRIPTION
99.1	Press Release, dated May 10, 2016, issued by Aralez Pharmaceuticals Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 10, 2016

ARALEZ PHARMACEUTICALS INC.

By: /s/ Eric L. Trachtenberg
Eric L. Trachtenberg
General Counsel, Chief Compliance Officer and
Corporate Secretary

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release, dated May 10, 2016, issued by Aralez Pharmaceuticals Inc.